Long COVID in Elderly Patients: An Epidemiologic Exploration Using a Medicare Cohort

Kin Wah Fung, MD

Fitsum Baye, MS

Seo H Baik, PhD

Zhaonian Zheng, MS

Clement J McDonald, MD

Affiliation: Lister Hill National Center for Biomedical Communications, National Library of Medicine, National Institutes of Health

Corresponding author:

Kin Wah Fung

kfung@mail.nih.gov

301-827-5001

8600 Rockville Pike, Bethesda, MD 20894

Word count: 4,534

1 Abstract

2	Background: Incidence of long COVID in the elderly is difficult to estimate and can be under-reported.
3	While long COVID is sometimes considered a novel disease, many viral or bacterial infections have been
4	known to cause prolonged illnesses. We postulate that some influenza patients might develop residual
5	symptoms that would satisfy the diagnostic criteria for long COVID, a condition we call "long Flu". In this
6	study, we estimate the incidence of long COVID and long Flu among Medicare patients using the World
7	Health Organization (WHO) consensus definition. We compare the incidence, symptomatology, and
8	healthcare utilization between long COVID and long Flu patients.

9

Methods and Findings: This is a cohort study of Medicare (the U.S. federal health insurance program) 10 11 beneficiaries over 65. ICD-10-CM codes were used to capture COVID-19, influenza and residual 12 symptoms. Long COVID was identified by a) the designated long COVID-19 code B94.8 (code-based 13 definition), or b) any of 11 symptoms identified in the WHO definition (symptom-based definition), from 14 one to 3 months post infection. A symptom would be excluded if it occurred in the year prior to 15 infection. Long Flu was identified in influenza patients from the combined 2018 and 2019 Flu seasons by the same symptom-based definition for long COVID. Long COVID and long Flu were compared in four 16 17 outcome measures: a) hospitalization (any cause), b) hospitalization (for long COVID symptom), c) emergency department (ED) visit (for long COVID symptom), and d) number of outpatient encounters 18 19 (for long COVID symptom), adjusted for age, sex, race, region, Medicare-Medicaid dual eligibility status, 20 prior-year hospitalization, and chronic comorbidities. Among 2,071,532 COVID-19 patients diagnosed 21 between April 2020 and June 2021, symptom-based definition identified long COVID in 16.6% 22 (246,154/1,479,183) and 29.2% (61,631/210,765) of outpatients and inpatients respectively. The 23 designated code gave much lower estimates (outpatients 0.49% (7,213/1,479,183), inpatients 2.6%

24	(5,521/210,765)). Among 933,877 influenza patients, 17.0% (138,951/817,336) of outpatients and 24.6%
25	(18,824/76,390) of inpatients fit the long Flu definition. Long COVID patients had higher incidence of
26	dyspnea, fatigue, palpitations, loss of taste/smell and neurocognitive symptoms compared to long Flu.
27	Long COVID outpatients were more likely to have any-cause hospitalization (31.9% (74,854/234,688) vs.
28	26.8% (33,140/123,736), odds ratio 1.06 (95% Cl 1.05-1.08, p<0.001)), and more outpatient visits than
29	long Flu outpatients (mean 2.9(SD 3.4) vs. 2.5(SD 2.7) visits, incidence rate ratio 1.09 (95% CI 1.08-1.10,
30	p<0.001)). There were less ED visits in long COVID patients, probably because of reduction in ED usage
31	during the pandemic. The main limitation of our study is that the diagnosis of long COVID in is not
32	independently verified.
33	
34	Conclusions: Relying on specific long COVID diagnostic codes results in significant under-reporting. We

35 observed that about 30% of hospitalized COVID-19 patients developed long COVID. In a similar

36 proportion of patients, long COVID-like symptoms (long Flu) can be observed after influenza, but there

37 are notable differences in symptomatology between long COVID and long Flu. The impact of long COVID

38 on healthcare utilization is higher than long Flu.

The quoted incidence of long COVID varies widely because of differences in definition and

40 Author summary

•

42

41 Why was this study done?

43	measurement method. Long COVID in the elderly is likely to be under-reported because they are
44	less likely to respond to surveys, and symptoms may be confused with other chronic diseases.
45	We describe a method of identifying long COVID in the elderly using a standard definition.
46	• Lingering ill health after infections is not limited to COVID-19. We postulate that some patients
47	may fit the diagnostic criteria of long COVID after a bout of influenza. We call this condition
48	"long Flu". Comparing and contrasting long COVID and long Flu may shed light on the
49	understanding of long COVID, a disease still shrouded in mystery.
50	What did the researchers do and find?
51	• We applied the World Health Organization consensus clinical definition to identify long COVID
52	among 2 million Medicare patients who were diagnosed with COVID-19 between April 2020 and
53	June 2021.
54	• We applied the symptom-based long COVID definition to almost 900,000 influenza patients
55	during the 2018 and 2019 Flu seasons to identify long Flu.
56	• Long COVID occurred in 16.6% of outpatients and 29.2% of inpatients. The corresponding rates
57	for long Flu were 17% and 24.6%. If one had relied solely on the designated diagnostic code to
58	identify long COVID, the estimated rates of long COVID would be 0.5% and 2.6% among
59	outpatients and inpatients, way below the reported rates in most studies.

							_	-
60	•	Despite the similar	r overall incidence i	rates long	nationts s	uffered r	nore often	from
00	•	Despice the similar		rates, iong	patients s	uncicui		

- 61 difficulty in breathing, fatigue, palpitations, loss of taste/smell, memory problems, cognitive
- 62 impairment and sleep disturbance than long Flu patients.
- Long COVID patients were also more likely to be admitted to hospital and had more outpatient
- 64 visits on average than long Flu patients.

65 What do these findings mean?

- The use of designated long COVID diagnostic codes alone is likely to result in gross under reporting.
- A similar proportion of influenza patients suffer from a prolonged illness resembling long COVID,
- but there are notable differences in the incidence of individual symptoms between long COVIDand long Flu.
- Long COVID is associated with higher level of healthcare utilization than long Flu. This means
- that long COVID is likely to have a bigger impact on the individual's health as well as on society
- as a whole.
- 74

75

- 76
- 77
- 78
- 79
- ,,,
- 80

81 1. Introduction

82	Most Coronavirus Disease 2019 (COVID-19) patients recover completely after an infection with the
83	SARS-CoV-2 virus. However, a proportion suffer from persistent health issues after the acute phase of
84	COVID-19 [1-7]. Various names have been used to describe this condition, including long COVID, long-
85	haulers, long-term effects of COVID-19, post-COVID syndrome, chronic COVID syndrome, post-COVID
86	conditions and post-acute sequelae SARS-CoV-2 infection (PASC). We shall use long COVID in this report.
87	Symptoms reported by long COVID patients range from fatigue, dyspnea, loss of smell to "brain fog".
88	The incidence of long COVID varies widely between studies, the majority are between 10% to 30% [8-
89	19]. According to one estimation, up to 23 million people in the U.S. may have developed long COVID as
90	of February 2022 [20]. Another study estimated that at least 3-5 million U.S. adults have activity-limiting
91	long COVID [21].
92	While it is known that elderly patients are more prone to develop severe COVID-19, some studies have
93	identified age as a risk factor also for long COVID [22, 23]. So far, relatively few long COVID studies have
94	focused on the elderly. Long COVID can be under reported in the elderly population because they may
95	not be as troubled by, or ready to report, the symptoms as in younger people [24]. They may also be less
96	likely to participate in Internet-based research or respond to questionnaires. Moreover, the long COVID
97	symptoms may be masked by or attributed to existing chronic diseases. One study finds that almost a
98	third of COVID-19 patients over 65 years developed one or more new or persistent clinical sequelae
99	[25]. Another study reports significant deterioration in quality of life and functional decline in elderly
100	patients 6 months after COVID-19 [26]. More information is needed to understand the impact of long
101	COVID on the elderly population.
102	While long COVID is sometimes considered a novel disease, it is hardly a totally unexpected

While long COVID is sometimes considered a novel disease, it is hardly a totally unexpected
phenomenon. Many viral or bacterial infections have been known to cause prolonged illnesses in a

104	subset of patients [27]. Rheumatic fever following infection by Streptococcus pyogenes is a well-known
105	example. Herpesviruses and enteroviruses are implicated in the cause of myalgic
106	encephalomyelitis/chronic fatigue syndrome (ME/CFS), characterized by fatigue, musculoskeletal pain
107	and post-exertional malaise [28]. First reports of prolonged symptoms after contracting Russian
108	influenza dated back to the 19 th century [10, 29]. More recently, the Severe Acute Respiratory Syndrome
109	Coronavirus (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have
110	been associated with post-acute phase persistent symptoms that affected approximately one-third of
111	patients [30].
112	There are a lot of similarities between COVID-19 and influenza. Both diseases are caused by easily

113 transmissible single-stranded RNA viruses primarily affecting the respiratory tract, with significant 114 systemic manifestations. Both diseases affect millions of patients every year, presenting substantial 115 medical and socioeconomic challenges. It is conceivable that, in some patients, a persistent state of ill 116 health, similar to long COVID, can occur after influenza [31]. Given the similarities between COVID-19 117 and influenza, we postulate that there is considerable overlap in the symptomatology of the post-viral 118 syndromes that they are associated with. This means that some patients suffering from post-flu 119 syndrome might meet the diagnostic criteria for long COVID, had the primary infection been COVID-19 120 instead of influenza. For lack of a better name, we shall call this condition "long Flu". Conceptually, long 121 Flu patients can serve as an "influenza comparator group" for long COVID. We think that comparing long 122 COVID and long Flu would bring new insights to the understanding of long COVID.

123 In this study, we develop a pragmatic algorithm to identify long COVID patients based on the clinical

definition proposed by the World Health Organization (WHO). Furthermore, we apply the same

algorithm to identify patients who may be suffering from long Flu in two previous influenza seasons

- 126 (2018 and 2019) and compare them with long COVID patients in three aspects: incidence,
- symptomatology, and impact on healthcare utilization.

128

129 2. Materials and methods

130 2.1 Study population

131 The primary cohort of this study was all Medicare patients over 65 diagnosed to have COVID-19 132 between April 2020 and June 2021. A control cohort of non-COVID-19 patients was identified by 1 to 5 133 matching for the same period. An influenza comparator cohort was identified from two pre-pandemic 134 influenza seasons in 2018 and 2019. Through the Virtual Research Data Center (VRDC) [32] of the 135 Centers for Medicare and Medicaid Services (CMS), we accessed de-identified encounter data of all 136 Medicare beneficiaries from 2016-2021. Medicare is the U.S. federal government's health insurance 137 program that primarily covers people 65 and older, and certain younger people with disabilities or 138 kidney failure. Most individuals become eligible for Medicare when they reach 65 [33]. By one estimate, 139 almost all (93%) of non-institutionalized persons 65 and over, about 52 million in 2017, are covered by 140 Medicare [34]. We focused our analysis only on Medicare beneficiaries aged \geq 65, since younger 141 Medicare beneficiaries are not representative of the general population aged <65 as they need 142 qualifying disability conditions to enroll. To ensure we have sufficient data for symptom look-up (see 143 below for method to identify long COVID and long Flu), we excluded patients a) with less than one year 144 of Medicare coverage, b) with no encounters in a year prior to COVID-19 or influenza diagnosis, c) who 145 were continuously enrolled in Medicare Advantage plans, mostly private health maintenance 146 organization (HMO) plans that are not original Medicare fee-for-service (FFS) plans in the period 147 between 1 year before and 12 weeks after the COVID-19 or influenza diagnosis. The last exclusion is 148 necessary because Medicare claims data are potentially incomplete for patients enrolled in non-FFS 149 plans. This study was declared not human subject research by the Office of Human Research Protection 150 at the National Institutes of Health and by the CMS's Privacy Board. There was no prospective analysis 151 protocol submitted before the commencement of this study.

152 **2.2 Identifying long COVID and long Flu**

153 2.2.1 Long COVID

154	We identified COVID-19 patients based on the International Classification of Disease-10 th Version-Clinical
155	Modification (ICD-10-CM) code U07.1 COVID-19, in either inpatient or outpatient claims between April
156	1, 2020, and June 30, 2021. We stopped at June 2021 to ensure that we have acquired complete data
157	for long COVID analysis because of several months' lag for claim maturity. We separated COVID-19
158	patients into two mutually exclusive groups: outpatient and inpatient. For outpatients, the first COVID-
159	19 diagnosis must be an outpatient coding, and the patient must not be admitted to an inpatient facility
160	(acute care hospital or skilled nursing facility (SNF)) for COVID-19 within 4 weeks of COVID-19 diagnosis.
161	A SNF is an in-patient rehabilitation and medical treatment center which provides a wide range of
162	medical care including physical therapy, intravenous therapy, injections, monitoring of vital signs and
163	medical equipment. For Inpatients, a) the first COVID-19 diagnosis must be an inpatient coding, or b) the
164	first COVID-19 diagnosis is an outpatient coding, but the patient must be admitted to an inpatient facility
101	
165	for COVID-19 within 4 weeks of the COVID-19 diagnosis.
165	for COVID-19 within 4 weeks of the COVID-19 diagnosis.
165 166	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended
165 166 167	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended ICD-10-CM code for long COVID, <i>B94.8 Sequelae of other specified infectious and parasitic diseases</i> ,
165 166 167 168	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended ICD-10-CM code for long COVID, <i>B94.8 Sequelae of other specified infectious and parasitic diseases,</i> during our study period (code-based definition). B94.8 can potentially be used in non-COVID-19
165 166 167 168 169	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended ICD-10-CM code for long COVID, <i>B94.8 Sequelae of other specified infectious and parasitic diseases,</i> during our study period (code-based definition). B94.8 can potentially be used in non-COVID-19 infections, but significant use of this code in Medicare data occurred only after April 2020 (usage
165 166 167 168 169 170	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended ICD-10-CM code for long COVID, <i>B94.8 Sequelae of other specified infectious and parasitic diseases,</i> during our study period (code-based definition). B94.8 can potentially be used in non-COVID-19 infections, but significant use of this code in Medicare data occurred only after April 2020 (usage increased over 20-fold), making it reasonably specific for long COVID. Note that after our study, a new
165 166 167 168 169 170 171	for COVID-19 within 4 weeks of the COVID-19 diagnosis. For identification of long COVID, we tried two approaches. The first was based on the recommended ICD-10-CM code for long COVID, <i>B94.8 Sequelae of other specified infectious and parasitic diseases,</i> during our study period (code-based definition). B94.8 can potentially be used in non-COVID-19 infections, but significant use of this code in Medicare data occurred only after April 2020 (usage increased over 20-fold), making it reasonably specific for long COVID. Note that after our study, a new specific code for long COVID, <i>U09.9 Post COVID-19 condition</i> , became available from October 2021.

based on a constellation of symptoms (symptom-based definition). We followed the WHO's clinical
definition that was developed through a consensus process involving over 200 experts, researchers and
patients [35]:

178 "Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-

179 CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at

180 least 2 months and cannot be explained by an alternative diagnosis. Common symptoms

181 *include fatigue, shortness of breath, cognitive dysfunction but also others which generally have*

182 an impact on everyday functioning. Symptoms may be new onset, following initial recovery

183 from an acute COVID-19 episode, or persist from the initial illness. Symptoms may also fluctuate

184 or relapse over time."

185 We used ICD-10-CM codes to identify the 11 symptoms that at least 50% of the participants in the 186 WHO's consensus building process thought were critical to include (see S1 Table for their incidence and 187 temporal trend). Long COVID was defined as presence of any of the 11 symptoms unless they were 188 excluded (see below for exclusion criteria). We also did a sensitivity analysis using only the top 3 189 symptoms (fatigue, shortness of breath, cognitive dysfunction) that reached 70% agreement in the 190 WHO's consensus building. For outpatients, we looked for symptoms from 4 to 12 weeks after the 191 COVID-19 diagnosis. For inpatients, we started looking for long COVID symptoms after they were 192 discharged to their original place of residence, following the recommendation from Amenta et al [36]. 193 The observation period for inpatients was from 2 to 10 weeks after discharge to compensate for the 194 median hospitalization period of 2 weeks.

We did not include SNF patients (9% of all COVID-19 patients) in the inpatient group because the
 proportion of COVID-19 patients admitted to SNF was unusually high (32.6%) compared to influenza
 patients in two previous Flu seasons (4.2%). More importantly, 88.6% of SNF COVID-19 patients were

198	not discharged home but transferred to different inpatient facilities at the end of our study period. Two
199	CMS policy changes in response to the pandemic may explain these phenomena: a) waiving of the three-
200	day requirement of prior hospital stay for admission to SNF, and b) the extension of SNF coverage for an
201	additional 100 days [37]. Since our identification of long COVID for inpatients started after their
202	discharge, most of SNF patients did not satisfy the inclusion criteria.
203	To satisfy the requirement that "[the symptom] cannot be explained by an alternative diagnosis", we
204	tried two approaches:
205	1. Exclusion by history – the long COVID symptom must not be present from 2 weeks to 1 year
206	before the COVID-19 diagnosis. We started the look-back period 2 weeks prior to COVID-19
207	diagnosis because COVID-19-related symptoms started to increase from 2 weeks before the
208	COVID-19 diagnosis, indicating a lag in diagnosis reporting (see S1 Table). Note that this
209	exclusion only applied to individual symptoms, not to the patient as a whole. For example, if a
210	patient had dyspnea 6 weeks after COVID-19 diagnosis, but the patient also complained of
211	dyspnea 6 months before COVID-19 diagnosis, then dyspnea would not be counted as a long
212	COVID symptom. However, the patient was not excluded and might still be identified as long
213	COVID due to other symptoms.
214	2. Exclusion by history and comorbidities – in addition to 1 above, we excluded symptoms that
215	could be explained by a known comorbidity, e.g., dyspnea excluded in the presence of chronic
216	obstructive pulmonary disease (see S2 Table for excluded symptoms). We used the chronic
217	condition onset dates in the Medicare database to identify comorbidities [38].
218	To estimate the false positive rate of the symptom-based definition, we matched each outpatient
219	COVID-19 case to 5 controls (never had the code U07.1 COVID-19 or Z86.16 Personal history of COVID-
220	19) on age in years, race, sex, dual-eligibility status (a surrogate for income), geographic region and

221	Charlson comorbidity index [39] (within a range of +/- 2). We applied the same symptom-based
222	definition on controls to assess the proportion of patients who would be falsely identified as long COVID.
223	2.2.2 Long Flu
224	Since the incidence of influenza diminished significantly during the COVID pandemic, we used data from
225	two pre-pandemic Flu seasons, October 2017 – May 2018 (2018 season) and October 2018 – May 2019
226	(2019 season) to estimate the incidence of the postulated long Flu. We identified influenza patients
227	using the ICD-10-CM codes J09, J10 and J11. Similar to COVID-19, we separated influenza patients into
228	outpatient and inpatient groups. We used the same list of long COVID symptoms and symptom
229	exclusion criteria to identify long Flu. The observation period was the same as for long COVID, i.e., from
230	4 to 12 weeks after influenza diagnosis for outpatients, and 2 to 10 weeks after discharge for inpatients.
231	We excluded all SNF influenza inpatients (0.5% of total) from the long Flu cohort to be comparable with
232	the long COVID cohort.

233 2.3 Comparing long COVID and long Flu

234 We compared the incidence and the distribution of symptoms between long COVID and long Flu patients. To estimate the impact of long COVID or long Flu on healthcare utilization, we analyzed four 235 236 outcomes: a) hospitalization (any cause), b) hospitalization (due to any long COVID symptom), c) 237 emergency department (ED) visit (due to any long COVID symptom), and d) number of outpatient 238 (excluding ED) encounters (due to any long COVID symptom). We ran analyses of each of four outcomes 239 separately for outpatients and hospitalized patients. For outpatients, we observed the outcomes for the 240 period 4-12 weeks post COVID-19 or influenza diagnosis. For inpatients, the observation period was 2-10 241 weeks post discharge.

242 2.4 Statistical analysis

243 We included all patients with COVID-19 or influenza, including those diagnosed with both. When we had 244 to compare COVID-19 and influenza patients statistically, we excluded patients who had both conditions 245 to ensure independence between groups. To test the difference in incidence of each specific symptom 246 between long COVID and long Flu patients, we first implemented a two-by-two contingency Chi-square 247 test [40], and used Hochberg method to control for familywise error rate from multiple hypotheses 248 testing by decreasing the number of false positives [41]. We then used a multiple logistic regression 249 model [42] to compare them further controlling for age, sex, race, region, dual eligibility and Charlson 250 comorbidity index and reported the adjusted odds ratios. We did not have to deal with missing data as 251 demographics and socioeconomic data were always present. 252 To test the difference in the first three outcomes of healthcare utilization (hospitalization any cause, 253 hospitalization with long COVID symptoms, ED visit with long COVID symptoms), we implemented a 254 generalized linear model with logit link adjusting for all available patient characteristics (age, sex, race, 255 geographical region, dual eligibility status, history of any hospitalization in prior year, and 55 chronic 256 conditions) as covariates. We adjusted for these covariates because demographics, comorbidities and 257 socioeconomic factors are known to affect healthcare utilization. To compare the number of outpatient 258 visits with long COVID symptoms, we used a generalized linear model with a log link function (i.e., 259 Poisson regression or log-linear regression analysis) with the same set of covariates as adjusters. We 260 used the generalized estimating equations (GEE) method to account for overdispersion in the Poisson 261 regression model. 262

The primary goal of this study is to estimate the incidence of long COVID in the elderly by various
approaches (code-based and symptom-based). Furthermore, we aim to compare the incidence,
symptomatology, and healthcare utilization of long COVID with the hypothetical condition of long Flu.

- 266 This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology
- 267 (STROBE) guideline (S1 Checklist).

268

- 269 3. Results
- 270 3.1 Patient characteristics
- 271 We began with 2,434,154 COVID-19, 1,033,515 influenza and 8,755,799 control Medicare beneficiaries
- aged ≥65. After applying exclusion criteria discussed in 2.1., we were left with 2,071,532 COVID-19
- patients of whom 1,479,183 (71.4%) were outpatients (Fig 1). We combined data from the two Flu
- seasons (2018 and 2019) because they were quite similar in terms of patients' health status and
- demographics (see S3 Table). There were 933,877 influenza patients of whom 817,336 (87.5%) were
- outpatients. All cases and controls were followed-up for 2 months to identify long COVID or long Flu,
- 277 making a total follow-up time of 1.5 million patient years.

278

279 Fig 1 Participant inclusion, exclusion, and matching

280

Table 1 shows the characteristics of the COVID-19 and influenza patients. Note that in comparing two groups, 91,796 COVID-19 patients who also had influenza in previous two Flu seasons were excluded (3% of total). Among the hospitalized patients, influenza patients were older and sicker (higher prior hospitalization rate and Charlson comorbidity index) than COVID-19 patients, but the difference was much smaller among outpatients.

286

287

288

	Outpatient			Inpatient (hospitalized)			
	COVID-19	Influenza ª	P value ^b	COVID-19	Influenza ª	P value ^b	
N (%)	1,479,183 (100)	817,336 (100)		399,124 (100)	111,721 (100)		
Any prior hospitalization ^c	349,688(23.6)	174,024(21.3)	<.0001	121,372(30.4)	42,868(38.4)	<.0001	
CCI, mean±SD	1.9±2.3	1.9±2.2	<.0001	2.6±2.6	3.0±2.6	<.0001	
Age, median (IQR)	75.0(70.0-82.0)	74.0(70.0-81.0)	<.0001	78.0(72.0-85.0)	81.0(74.0-88.0)	<.0001	
65-69	313,613(21.2)	185,573(22.7)	<.0001	58,643(14.7)	11,826(10.6)	<.0001	
70-74	389,872(26.4)	225,954(27.6)	<.0001	86,543(21.7)	18,726(16.8)	<.0001	
75-79	277,075(18.7)	160,188(19.6)	<.0001	79,671(20.0)	20,232(18.1)	<.0001	
80-84	205,435(13.9)	110,568(13.5)	<.0001	70,961(17.8)	20,733(18.6)	<.0001	
85+	293,188(19.8)	135,053(16.5)	<.0001	103,306(25.9)	40,204(36.0)	<.0001	
Female	853,157(57.7)	491,113(60.1)	<.0001	201,712(50.5)	65,020(58.2)	<.0001	
Race: White	1,165,494(78.8)	664,540(81.3)	<.0001	296,000(74.2)	92,339(82.7)	<.0001	
Black	117,273(7.9)	55 <i>,</i> 488(6.8)	<.0001	46,349(11.6)	8,637(7.7)	<.0001	
Hispanic	111,488(7.5)	50,594(6.2)	<.0001	34,782(8.7)	6,176(5.5)	<.0001	
Asian	37,698(2.5)	24,401(3.0)	<.0001	9,870(2.5)	2,448(2.2)	<.0001	
Other	47,230(3.2)	22,313(2.7)	<.0001	12,123(3.0)	2,121(1.9)	<.0001	
Region: Northeast	322,838(21.8)	131,762(16.1)	<.0001	76,301(19.1)	22,251(19.9)	<.0001	
Midwest	309,689(20.9)	160,077(19.6)	<.0001	97,444(24.4)	30,757(27.5)	<.0001	
South	566,699(38.3)	384,311(47.0)	<.0001	164,849(41.3)	38,622(34.6)	<.0001	
West	265,878(18.0)	129,759(15.9)	<.0001	57,326(14.4)	18,873(16.9)	<.0001	
Income: Ever Dual	367,459(24.8)	156,074(19.1)	<.0001	108,094(27.1)	28,562(25.6)	<.0001	
Non-Dual LIS	21,666(1.5)	14,397(1.8)	<.0001	8,806(2.2)	2,466(2.2)	<.0001	
Non-Dual Non-LIS	1,090,058(73.7)	646,865(79.1)	<.0001	282,224(70.7)	80,693(72.2)	<.0001	

289 Table 1. Characteristics of COVID-19 and influenza patients (CCI – Charlson comorbidity index, SD –

290 standard deviation, IQR – inter-quartile range, LIS – low-income subsidy)

^a combined 2018 & 2019 Flu seasons

^b excluding 91,796 patients with both COVID-19 and influenza

^c any prior hospitalization within one year of COVID-19 or influenza diagnosis

294

Each COVID-19 outpatient was matched to 5 non-COVID-19 patients. Overall, there were 6,286,633

296 controls with unmatched rate (COVID-19 patients unable to be matched) of 1.1% . The cases and

297 controls were generally quite well matched in terms of demographics and Charlson comorbidity index -.

298 Due to the large sample size, most differences between cases and controls were statistically significant

but the absolute standardized difference <0.25 indicated good balance between them (S4 Table) [43].

300 3.2 Incidence of long COVID and long Flu

301	Among the hospitalized COVID-19 and influenza patients, 52.8% (210,765/399,124) and 68.4%
302	(76,390/111,721) respectively were discharged to their original place of residence by the end of our
303	study period. These patients were used to estimate the incidence of long COVID and long Flu in
304	inpatients. Based on the ICD-10-CM diagnosis code of B94.8 (i.e., the code-based definition), only 0.49%
305	of outpatients and 2.6% of hospitalized patients were identified to develop long COVID (Table 2), way
306	lower than most published reports. Using the symptom-based definition, the estimated incidence of
307	long COVID was closest to other studies when we applied the definition of "any of 11 symptoms with
308	history exclusion only". By this definition, the incidence of long COVID was 16.6% and 29.2% in
309	outpatients and hospitalized patients respectively. If we added the comorbidity exclusion to this
310	definition, the rates would drop to 5.7% (outpatient) and 8.8% (inpatient). We shall use the "any of 11
311	symptoms with history exclusion only" definition as our main result in subsequent discussion.

Long COVID definition	Outpatient		Inpatient (h	ospitalized)	Control
	COVID-19	Influenza	COVID-19	Influenza	Matched with COVID- 19 outpatient
N(%)	1,479,183(100)	817,336(100)	210,765(100)	76,390(100)	6,286,633(100)
Code-based (B94.8)	7,213(0.49)	39(<0.01)	5,521(2.6)	11(0.01)	264 (<0.01)
Symptom-based					
Any of 11 symptoms with history exclusion only	246,154(16.6)	138,951(17.0)	61,631(29.2)	18,824(24.6)	658,229(10.5)
Any of 11 symptoms with history and comorbidity exclusion	84,774(5.7)	50,616(6.2)	18,486(8.8)	4,804(6.3)	220,751(3.5)
Any of 3 main symptoms with history exclusion only	142,175(9.6)	70,680(8.7)	42,690(20.3)	10,907(14.3)	357,915(5.7)
Any of 3 main symptoms with history and comorbidity exclusion	54,754(3.7)	30,053(3.7)	13,531(6.4)	3,302(4.3)	148,251(2.4)

312 Table 2. Incidence of long COVID and long Flu by various definitions

313

314 **3.3 Difference in symptomatology of long COVID and long Flu**

- After excluding 91,796 patients with both COVID-19 and influenza (3% of all COVID-19 and influenza patients), we had 293,172 long COVID patients (outpatient 234,688, inpatient 58,484) and 140,697 long Flu patients (outpatient 123,736, inpatient 16,961) (Table 3). Rates of dyspnea, fatigue, palpitations, and loss of taste/smell were significantly higher in long COVID than long Flu, among both outpatients and hospitalized patients. In contrast, cough, chest pain, headache, and muscle/joint pain were more frequent in long Flu in both outpatient and inpatient groups. The incidence of memory problem, cognitive impairment and sleep disturbance were significantly higher in long COVID among outpatients
- 322 only.

Symptoms	Long COVID (%)	Long Flu (%)	P value ^a	Adjusted OR (95% CI) ^b
Outpatient	N=234,688(100)	N=123,736(100)		
dyspnea	66,562(28)	29,689(24)	<0.001	1.25(1.23,1.27)
fatigue/malaise/weakness	76,881(33)	36,547(30)	<0.001	1.15(1.13,1.16)
cough	45,776(20)	32,192(26)	<0.001	0.69(0.67,0.70)
chest pain	41,697(18)	22,538(18)	0.002	0.97(0.95,0.99)
palpitations	31,120(13)	13,940(11)	<0.001	1.20(1.18,1.23)
headache	17,950(8)	10,637(9)	<0.001	0.89(0.87,0.91)
muscle/ joint pain	14,097(6)	8,332(7)	<0.001	0.91(0.88,0.93)
memory problem	8,261(4)	4,097(3)	0.002	1.09(1.05,1.13)
cognitive impairment	6,698(3)	2,671(2)	<0.001	1.29(1.23,1.35)
sleep disturbance	2,360(1)	1,148(0.9)	0.024	1.10(1.02,1.18)
loss of taste/smell	1,537(0.7)	414(0.3)	<0.001	2.02(1.81,2.26)
Inpatient (hospitalized)	N=58,484(100)	N=16,961(100)		
dyspnea	24,915(43)	5,186(31)	<0.001	1.51(1.45,1.57)
fatigue/malaise/weakness	20,500(35)	5,424(32)	<0.001	1.25(1.21,1.30)
cough	11,425(20)	4,247(25)	<0.001	0.69(0.66,0.72)
chest pain	9,773(17)	3,065(18)	<0.001	0.91(0.87,0.95)
palpitations	8,467(14)	2,054(12)	<0.001	1.22(1.15,1.28)
headache	3,026(5)	1,288(8)	<0.001	0.71(0.66,0.76)
muscle/ joint pain	2,103(4)	715(4)	<0.001	0.86(0.79,0.94)
memory problem	1,849(3)	648(4)	0.034	0.91(0.83,1.00)
cognitive impairment	1,066(2)	401(2)	<0.001	0.89(0.79,1.01)
sleep disturbance	508(0.9)	137(0.8)	0.448	1.09(0.90,1.33)
loss of taste/smell	288(0.5)	42(0.3)	<0.001	2.04(1.47,2.83)

323 Table 3. Symptoms in long COVID and long Flu patients (OR – odds ratio of developing each specific

324 symptom for long COVID compared to long Flu, CI – confidence interval)

325 • adjusted for multiple hypothesis testing from Chi-Square test

^b adjusted for age, sex, race, region, dual eligibility and Charlson comorbidity index

328 3.4 Difference in healthcare utilization in long COVID and long Flu

- 329 For both outpatients and hospitalized patients, long COVID was associated with significantly higher
- 330 chance of any hospitalizations and more outpatient visits than long Flu (Table 4). The difference is
- especially notable among hospitalized patients, even though hospitalized influenza patients, at the
- baseline, were sicker and older than hospitalized COVID-19 patients, which should normally translate
- into more healthcare utilization. In contrast, the likelihood of an ED visit was significantly higher among
- 334 long Flu patients.

	Healthcare utilization			
	Any hospitalization (%)	Symptom-specific ^a hospitalization (%)	Symptom-specific ^a ED visit (%)	Number of symptom-specific a outpatient visits, mean (SD)
Outpatient				
Long COVID, N=234,688	74,854(31.9)	36,721(15.6)	25,131(10.7)	2.9(3.4)
Long Flu, N=123,736	33,140(26.8)	16,065(13.0)	15,566 (12.6)	2.5(2.7)
Inpatient (hospitalized)				
Long COVID, N=58,484	20,182(34.5)	8,286(14.2)	7,816(13.4)	2.9(3.2)
Long Flu, N=16,961	6,245(36.8)	2,593(15.3)	2,749(16.2)	2.8(3.0)
Comparative risk of long				
COVID patients relative to long Flu patients ^b	OR (95%Cl, p value)	OR (95%Cl, p value)	OR (95%Cl, p value)	IRR (95%CI, p value)
Outpatient	1.06(1.05,1.08, <0.001)	1.00(0.98,1.02, 0.979)	0.80(0.78,0.82, <0.001)	1.09(1.08,1.10, <0.001)
Inpatient (hospitalized)	1.24(1.19,1.29, <0.001)	1.20(1.14,1.27, <0.001)	0.90(0.86,0.95, <0.001)	1.09(1.07,1.11, <0.001)

Table 4. Healthcare utilization of long COVID and long Flu patients (ED – emergency department, SD –
 standard deviation, OR – odds ratio, IRR – incidence rate ratio, CI – confidence interval)

337 ^a with any of the 11 symptoms of long COVID

338 ^b adjusted for age, sex, race, geographical region, dual eligibility status, history of any hospitalization in prior year, and chronic comorbidities

339

- 341 4. Discussion
- 342 One major hurdle in long COVID-19 research is the difficulty in identifying long COVID cases. Due to the
- 343 wide range of definitions, the results of studies often cannot be compared or generalized [12]. The
- development of a consensus on clinical definition by the WHO partially fills this gap [35]. Our study has

345 developed a method to operationalize this clinical definition. The WHO definition depends on the 346 presence of a constellation of symptoms but requires that the symptoms do not have an alternative 347 explanation. Identifying such explanations can be done in observational studies. We compared two 348 approaches – exclusion by history (the symptom did not occur within the previous year) and exclusion 349 by history and comorbidities. The use of exclusion by history alone yields estimates of long COVID of 350 16.6% in outpatients and 29.2% in hospitalized patients, which are close to many published results. A 351 recent large meta-analysis covering 194 studies shows that on average, at least 45% of COVID-19 352 survivors (non-hospitalized patients 34.5%, hospitalized patients 52.6%) continue to experience at least 353 one unresolved symptom [44]. This means that our results are likely to be an under-estimation. One 354 potential problem of exclusion of individual symptoms based on history is that common symptoms are 355 more likely to be excluded, even if they are indeed related to long COVID. In our study, the incidence of 356 cognitive impairment and memory problem among long COVID patients is lower than that reported in 357 the literature [44]. Since these problems are generally more common among elderly patients, they are 358 more likely to be excluded by coincidence. Another factor that can be at play is that the threshold of 359 seeking help for these problems may be higher in elderly patients. Adding the exclusion based on comorbidities cuts the estimates significantly to 5.7% for outpatients and 8.8% for hospitalized patients. 360 361 We speculate that the comorbidity exclusion is probably too strict because some comorbidities are very 362 prevalent in our study population of elderly Medicare beneficiaries. For example, high prevalence of 363 heart failure (43%), chronic obstructive pulmonary disease (41%), and fibromyalgia chronic pain and 364 fatigue (54%) would lead to exclusion of cough, dyspnea, and fatigue.

A recent study shows promise in the use of machine learning to identify long COVID [45]. However, the model in Pfaff et al. was only built on a very small, 0.6%, subset of 97,995 COVID-19 patients attending a long COVID clinic, highlighting the difficulty of identifying *all* patients suffering from long COVID. For machine learning methods to be effective, a large number of cases along with high-quality data is

369 required. Achieving this goal can be difficult because long COVID tends to be under-reported and under-370 coded [46]. In our study, code-based identification of long COVID vields an estimation of only 0.49% in 371 outpatients and 2.6% in hospitalized patients, way below published results. A specific long COVID code, 372 U09.9, was delivered in October 2021, however, healthcare providers were slow to take advantage of 373 this code [47]. Based on additional data from September to December 2021, which became available 374 after our study concluded, we found that the new long COVID code (U09.9) was used more often than 375 the old one (B94.8), whose usage dropped off significantly. Using the new code in our code-based 376 definition, 2.0% (11,424/573,965) of outpatients and 9.2% (6,253/68,030) of hospitalized patients 377 developed long COVID. This is still considerably lower than most reports in the literature. Researchers 378 should be aware of the potential under-reporting if they rely solely on specific codes to identify long COVID. 379 380 We postulate the existence of "long Flu" based on reports of post-infectious sequelae after influenza 381 [29]. Long COVID has attracted special attention because of the pandemic, but the possible occurrence 382 of prolonged symptoms from influenza should not be overlooked. Long COVID is still a poorly 383 understood disease. Comparing and contrasting long COVID with long Flu may offer new insights into its pathogenesis and treatment. The pathogenesis of long COVID is likely to be complex and more than one 384 385 mechanism may be implicated in some clinical manifestations [28, 48]. Evidence suggests that prolonged 386 inflammation probably plays a key role. In addition, it is known that, like other coronaviruses, SARS-CoV-387 2 can invade the blood-brain barrier and access the central nervous system through peripheral or 388 olfactory neurons [49, 50]. This could explain the greater incidence of psychoneurological symptoms 389 (e.g., cognitive impairment, loss of taste or smell, memory problem and sleep disturbance) in long 390 COVID compared to long Flu in our study. Another special feature of COVID-19 is the high incidence of 391 thromboembolism, probably as a result of endothelial injury and heightened inflammation, which can 392 lead to organ or tissue injury [51, 52]. Investigators have found high incidence of significant radiological

and functional abnormalities indicative of lung parenchymal and small airway disease after the acute
 phase of COVID-19, which could give rise to dyspnea and easy fatigue [53].

395 Based on our estimation, the incidence of long COVID and long Flu is comparable among outpatients 396 (16.6% vs. 17.0%), and slightly higher for long COVID in inpatients (29.2% vs. 24.6%). But incidence alone 397 doesn't tell the whole story about the impact of the two diseases. Our model on healthcare utilization 398 shows that long COVID patients are more likely to seek outpatient care and be hospitalized, after 399 controlling for demographics, socioeconomic factors, and comorbidities. This suggests that long COVID is 400 a more serious illness than long Flu and has greater societal impact. One unexpected finding is the 401 reduced ED visits in long COVID patients. This is probably an anomaly and could be explained by the fact 402 that overall, ED visits shrunk during the pandemic, possibly because patients fearing exposure to COVID-403 19 avoided the ED for conditions for which they otherwise would have sought emergency care. Long flu 404 data came from 2017-2019, and we observed that the overall usage of ED dropped by 18% in 2020 405 compared with 2017-2019 among Medicare senior beneficiaries.

406 We recognize the following limitations. Based on our exclusion criteria, 15% of COVID-19 patients, 10% 407 of influenza patients and 28% of matched controls were excluded, which may affect the generalizability 408 of our findings. Not all COVID-19 diagnoses are captured in Medicare claims data. Our previous study 409 showed that up to one-third of COVID-19 cases could be missed [54]. Medicare claims-based data may 410 miss services or treatment paid for by private insurance or other means. The code-based definition of 411 long COVID is based on the recommended code available for the study period, which may not be specific for long COVID. The symptom-based definition relies on the symptoms reported as "diagnosis" at the 412 413 healthcare encounter and may not be sensitive because providers may not routinely code all symptoms. 414 Using claims data, we cannot easily ascertain the duration of the symptoms as stipulated in the WHO 415 definition. There is no independent confirmation that patients identified by our method are indeed 416 suffering from long COVID. However, we can venture some estimation of our error rates. False positive

417	rate can be estimated by the positive rate in controls (10.5%). Among the 12,734 patients specifically
418	coded as long COVID (code-based definition), 8,239 (64.7%) patients were identified as long COVID by
419	the symptom-based definition, so the false negative rate can be estimated to be about 35%. If we adjust
420	our results by these estimated error rates, the incidence of long COVID would be 9% for outpatients and
421	28% for inpatients, still not far from other studies. Our observation period ends at 12 weeks after the
422	COVID-19 or influenza diagnosis. Some patients may present with long COVID or long Flu after that
423	period. Among the inpatients, we exclude SNF patients because a significant proportion of them are not
424	discharged within the study period. We assume that long Flu is similar to long COVID and use the same
425	symptomatic definition. There may be symptoms in post-influenza syndrome that are not common in
426	long COVID, and patients with those symptoms may not be identified as long Flu in our study.
427	Based on a constellation of symptoms identified in the WHO's consensus definition, we estimate that
428	long COVID occurs in 16.6% and 29.2% of elderly COVID-19 outpatients and inpatients respectively. The
429	corresponding incidence for long Flu, identified by the same constellation of symptoms for two pre-
430	pandemic influenza seasons, is about the same (17% and 24.6%). Long COVID patients have significantly
431	higher incidence of dyspnea, fatigue, palpitations, loss of taste or smell, and neurocognitive symptoms.
432	Compared to long Flu, patients with long COVID are hospitalized more often and have more outpatient
433	visits, suggesting that it is a more serious illness and has higher societal impact.
434	

441 References

Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.
 Nature. 2021;594(7862):259-64. Epub 2021/04/23. doi: 10.1038/s41586-021-03553-9. PubMed PMID:
 33887749.
 Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA.

446 2020;324(17):1723-4. Epub 2020/10/09. doi: 10.1001/jama.2020.19719. PubMed PMID: 33031513;
447 PubMed Central PMCID: PMCPMC8019677.

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in
patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32. Epub 2021/01/12.

doi: 10.1016/S0140-6736(20)32656-8. PubMed PMID: 33428867; PubMed Central PMCID:
 PMCPMC7833295.

4. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric
outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health
records. Lancet Psychiatry. 2021;8(5):416-27. Epub 2021/04/10. doi: 10.1016/S2215-0366(21)00084-5.
PubMed PMID: 33836148; PubMed Central PMCID: PMCPMC8023694 no competing interests.

456 5. Wanga V, Chevinsky JR, Dimitrov LV, Gerdes ME, Whitfield GP, Bonacci RA, et al. Long-Term
457 Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. MMWR Morb
458 Mortal Wkly Rep. 2021;70(36):1235-41. Epub 2021/09/10. doi: 10.15585/mmwr.mm7036a1. PubMed
459 PMID: 34499626; PubMed Central PMCID: PMCPMC8437054 Journal Editors form for disclosure of
460 potential conflicts of interest. No potential conflicts of interest were disclosed.

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al.
 More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep.
 2021;11(1):16144. Epub 2021/08/11. doi: 10.1038/s41598-021-95565-8. PubMed PMID: 34373540;
 PubMed Central PMCID: PMCPMC8352980.

Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After
Acute COVID-19. JAMA. 2020;324(6):603-5. Epub 2020/07/10. doi: 10.1001/jama.2020.12603. PubMed
PMID: 32644129; PubMed Central PMCID: PMCPMC7349096.

468 8. Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms,
469 and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. 2021;75(10):e14357. Epub
470 2021/05/13. doi: 10.1111/ijcp.14357. PubMed PMID: 33977626; PubMed Central PMCID:
471 PMCPMC8236920.

472 9. Ahmad MS, Shaik RA, Ahmad RK, Yusuf M, Khan M, Almutairi AB, et al. "LONG COVID": an
473 insight. Eur Rev Med Pharmacol Sci. 2021;25(17):5561-77. Epub 2021/09/18. doi:

474 10.26355/eurrev_202109_26669. PubMed PMID: 34533807.

Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID,
a comprehensive systematic scoping review. Infection. 2021;49(6):1163-86. Epub 2021/07/29. doi:
10.1007/s15010-021-01666-x. PubMed PMID: 34319569; PubMed Central PMCID: PMCPMC8317481.

478 11. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term

479 Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open.

480 2021;4(10):e2128568. Epub 2021/10/14. doi: 10.1001/jamanetworkopen.2021.28568. PubMed PMID:
481 34643720; PubMed Central PMCID: PMCPMC8515212.

Rando HM, Bennett TD, Byrd JB, Bramante C, Callahan TJ, Chute CG, et al. Challenges in defining
Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported
information. medRxiv. 2021. Epub 2021/04/02. doi: 10.1101/2021.03.20.21253896. PubMed PMID:

485 33791733; PubMed Central PMCID: PMCPMC8010765.

486 13. Huang Y, Pinto MD, Borelli JL, Mehrabadi MA, Abrihim H, Dutt N, et al. COVID Symptoms,

487 Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the

488 Pandemic. medRxiv. 2021. Epub 2021/03/11. doi: 10.1101/2021.03.03.21252086. PubMed PMID: 489 33688670; PubMed Central PMCID: PMCPMC7941647. 490 Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-14. 491 Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325(15):1525-34. Epub 2021/03/18. doi: 10.1001/jama.2021.3331. PubMed PMID: 33729425; 492 493 PubMed Central PMCID: PMCPMC7970386. 494 Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, et al. Population-Based 15. 495 Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 496 Infection (PASC) Prevalence and Characteristics. Clin Infect Dis. 2021;73(11):2055-64. Epub 2021/05/20. 497 doi: 10.1093/cid/ciab408. PubMed PMID: 34007978; PubMed Central PMCID: PMCPMC8240848. 498 16. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, et al. Post-acute effects of SARS-499 CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. 500 Lancet Infect Dis. 2021;21(10):1373-82. Epub 2021/05/14. doi: 10.1016/S1473-3099(21)00211-5. 501 PubMed PMID: 33984263; PubMed Central PMCID: PMCPMC8110209 participation in research projects 502 funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, and LEO 503 Pharma, outside the the current work. LCL reports funds paid to his institution for participation in 504 research projects funded by Menarini Pharmaceuticals and LEO Pharma, outside the current work. HN 505 reports funds paid to their institution for participation in research projects funded by Merck Sharp & 506 Dohme and Novo Nordisk Foundation, outside the current work. The institution of CFC and RWT is 507 involved in studies with funding from various companies as research grants to (and administered by) 508 Aarhus University, outside the current work. AK, SHM, and NCB report no competing interests. 509 17. Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-Acute Sequelae of SARS-510 CoV-2 Infection Among Adults Aged >/=18 Years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(37):1274-7. Epub 2021/09/17. doi: 511 512 10.15585/mmwr.mm7037a2. PubMed PMID: 34529639; PubMed Central PMCID: PMCPMC8445372 513 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest 514 were disclosed. 515 Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in 18. 516 Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2):e210830. Epub 2021/02/20. 517 doi: 10.1001/jamanetworkopen.2021.0830. PubMed PMID: 33606031; PubMed Central PMCID: 518 PMCPMC7896197. 519 19. UK Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-520 19) infection in the UK. Sept 2021 dataset. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/ 521 522 datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk. 523 20. U.S. Government Accountability Office. Science & Tech Spotlight: Long COVID. Available from: 524 https://www.gao.gov/products/gao-22-525 105666?utm source=onepager&utm medium=email&utm campaign=email staa. 526 Tenforde MW, Devine OJ, Reese HE, Silk BJ, Iuliano AD, Threlkel R, et al. Point Prevalence 21. 527 Estimates of Activity-Limiting Long-Term Symptoms among U.S. Adults >/=1 Month After Reported SARS-CoV-2 Infection, November 1, 2021. J Infect Dis. 2022. Epub 2022/07/02. doi: 528 529 10.1093/infdis/jiac281. PubMed PMID: 35776165; PubMed Central PMCID: PMCPMC9278232. 530 22. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and 531 predictors of long COVID. Nat Med. 2021;27(4):626-31. Epub 2021/03/12. doi: 10.1038/s41591-021-532 01292-y. PubMed PMID: 33692530; PubMed Central PMCID: PMCPMC7611399. 533 23. Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al. Long-COVID: An 534 evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10-2. Epub 2021/01/07. doi: 535 10.7196/SAMJ.2020.v111i11.15433. PubMed PMID: 33403997.

536 Graham J. 'That's Just Part of Aging': Long Covid Symptoms Are Often Overlooked in Seniors. 24. 537 Kaiser Health News. Available from: https://khn.org/news/article/long-covid-symptoms-seniors/. Cohen K, Ren S, Heath K, Dasmarinas MC, Jubilo KG, Guo Y, et al. Risk of persistent and new 538 25. 539 clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 540 infection: retrospective cohort study. BMJ. 2022;376:e068414. Epub 2022/02/11. doi: 10.1136/bmj-541 2021-068414. PubMed PMID: 35140117; PubMed Central PMCID: PMCPMC8828141 at 542 www.icmje.org/coi disclosure.pdf and declare: support from Optum Laboratories for the submitted 543 work; no financial relationships with any organizations that might have an interest in the submitted 544 work in the previous three years; no other relationships or activities that could appear to have 545 influenced the submitted work. KC declares consulting from Pfizer. ML declares honoraria/consulting 546 from Merck, Sanofi-Pasteur, Bristol Myers-Squibb, and Antigen Discovery; research funding 547 (institutional) from Pfizer; and unpaid scientific advisory services to Janssen, Astra-Zeneca, One Day 548 Sooner, and Covaxx (United Biomedical). 549 Walle-Hansen MM, Ranhoff AH, Mellingsaeter M, Wang-Hansen MS, Myrstad M. Health-related 26. 550 quality of life, functional decline, and long-term mortality in older patients following hospitalisation due 551 to COVID-19. BMC Geriatr. 2021;21(1):199. Epub 2021/03/24. doi: 10.1186/s12877-021-02140-x. PubMed PMID: 33752614; PubMed Central PMCID: PMCPMC7983098. 552 553 27. Bannister BA. Post-infectious disease syndrome. Postgrad Med J. 1988;64(753):559-67. Epub 554 1988/07/01. doi: 10.1136/pgmj.64.753.559. PubMed PMID: 3074289; PubMed Central PMCID: 555 PMCPMC2428896. 556 28. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview 557 of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169. 558 Epub 2021/07/13. doi: 10.3389/fmicb.2021.698169. PubMed PMID: 34248921; PubMed Central PMCID: 559 PMCPMC8260991. 560 29. Honigsbaum M, Krishnan L. Taking pandemic sequelae seriously: from the Russian influenza to 561 COVID-19 long-haulers. Lancet. 2020;396(10260):1389-91. Epub 2020/10/16. doi: 10.1016/S0140-562 6736(20)32134-6. PubMed PMID: 33058777; PubMed Central PMCID: PMCPMC7550169. Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical 563 30. 564 outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome 565 coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J 566 Rehabil Med. 2020;52(5):jrm00063. Epub 2020/05/26. doi: 10.2340/16501977-2694. PubMed PMID: 567 32449782. Chen J, Wu J, Hao S, Yang M, Lu X, Chen X, et al. Long term outcomes in survivors of epidemic 568 31.

568 S1. Cherry, Wu J, Hao S, Fang M, Eu X, Cherr X, et al. Long term outcomes in survivors of epidemic
 569 Influenza A (H7N9) virus infection. Sci Rep. 2017;7(1):17275. Epub 2017/12/10. doi: 10.1038/s41598 570 017-17497-6. PubMed PMID: 29222500; PubMed Central PMCID: PMCPMC5722861.

570 017-17497-6. PubMed PMID: 29222500; PubMed Central PMCID: PMCPMC5722861.
571 32. Research Data Assistance Center (ResDAC). CMS Virtual Research Data Center (VRDC). Available

572 from: https://www.resdac.org/cms-virtual-research-data-center-vrdc.

573 33. Kaiser Family Foundation. A Primer on Medicare - Key facts about the Medicare program and

the people it covers. Available from: <u>https://files.kff.org/attachment/report-a-primer-on-medicare-key-</u>
 <u>facts-about-the-medicare-program-and-the-people-it-covers</u>.

- Administration on Aging U.S. Department of Health and Human Services. 2018 Profile of Older
 Americans. Available from: <u>https://acl.gov/aging-and-disability-in-america/data-and-research/profile-</u>
 <u>older-americans</u>.
- 579 35. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi
- 580 consensus. Available from: <u>http://www.fx1234.com/iris/bitstream/handle/10665/345824/WHO-2019-</u>

581 <u>nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1&isAllowed=y</u>.

582 36. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute 583 COVID-19: An Overview and Approach to Classification. Open Forum Infect Dis. 2020;7(12):ofaa509.

584 Epub 2021/01/07. doi: 10.1093/ofid/ofaa509. PubMed PMID: 33403218; PubMed Central PMCID: 585 PMCPMC7665635. 586 Center for Medicare Advocacy. Expanded Medicare Skilled Nursing Facility Coverage During the 37. 587 Covid-19 Pandemic. Available from: https://medicareadvocacy.org/snf-limitations-waived-during-covid/. 588 Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse: CCW Chronic 38. 589 Condition Algorithms. . Available from: https://www.ccwdata.org/web/guest/condition-categories. 590 Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The 39. 591 Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin 592 Epidemiol. 2008;61(12):1234-40. Epub 2008/07/16. doi: 10.1016/j.jclinepi.2008.01.006. PubMed PMID: 593 18619805. 594 40. Agresti A, Kateri M. Categorical Data Analysis. 2011. p. 206-8. 595 41. Chen S-Y, Feng Z, Yi X. A general introduction to adjustment for multiple comparisons. Journal of 596 Thoracic Disease. 2017;9(6):1725-9. 597 Berkson J. Application of the Logistic Function to Bio-Assay. Journal of the American Statistical 42. 598 Association. 1944;39(227):357-65. doi: 10.2307/2280041. 599 Rubin DB. Using Propensity Scores to Help Design Observational Studies: Application to the 43. 600 Tobacco Litigation. Health Services and Outcomes Research Methodology. 2001;2(3):169-88. doi: 601 10.1023/A:1020363010465. 602 44. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-603 term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic 604 review and meta-analysis. EClinicalMedicine. 2023;55:101762. Epub 2022/12/08. doi: 605 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID: PMCPMC9714474. 606 45. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. Identifying who has long 607 COVID in the USA: a machine learning approach using N3C data. The Lancet Digital Health. 608 2022;4(7):e532-e41. doi: https://doi.org/10.1016/S2589-7500(22)00048-6. 609 Walker AJ, MacKenna B, Inglesby P, Tomlinson L, Rentsch CT, Curtis HJ, et al. Clinical coding of 46. 610 long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. British Journal of General Practice. 2021;71(712):e806-e14. doi: 611 612 10.3399/bjgp.2021.0301. 613 47. Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding Long COVID: 614 Characterizing a new disease through an ICD-10 lens. medRxiv. 2022:2022.04.18.22273968. doi: 615 10.1101/2022.04.18.22273968. Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines 616 48. 617 (Basel). 2021;9(5). Epub 2021/06/03. doi: 10.3390/vaccines9050497. PubMed PMID: 34066007; PubMed 618 Central PMCID: PMCPMC8151752. 619 49. Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-620 CoV-2 in human and mouse brain. bioRxiv. 2020:2020.06.25.169946. doi: 10.1101/2020.06.25.169946. 621 50. Ritchie K, Chan D, Watermeyer T. The cognitive consequences of the COVID-19 epidemic: 622 collateral damage? Brain Communications. 2020;2(2). doi: 10.1093/braincomms/fcaa069. 623 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and 51. 624 Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and 625 Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-73. Epub 2020/04/21. doi: 626 10.1016/j.jacc.2020.04.031. PubMed PMID: 32311448; PubMed Central PMCID: PMCPMC7164881. 627 Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid 52. 628 Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38. Epub 2020/04/09. doi: 629 10.1056/NEJMc2007575. PubMed PMID: 32268022; PubMed Central PMCID: PMCPMC7161262. 630 53. Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux P-O, Brutsche M, Clarenbach C, et al. 631 Pulmonary function and radiological features 4 months after COVID-19: first results from the national

- 632 prospective observational Swiss COVID-19 lung study. European Respiratory Journal.
- 633 2021;57(4):2003690. doi: 10.1183/13993003.03690-2020.
- 54. Fung KW, Baik SH, Baye F, Zheng Z, Huser V, McDonald CJ. Effect of common maintenance drugs
- on the risk and severity of COVID-19 in elderly patients. PLoS One. 2022;17(4):e0266922. Epub
- 636 2022/04/19. doi: 10.1371/journal.pone.0266922. PubMed PMID: 35436293; PubMed Central PMCID:
- 637 PMCPMC9015134.

- 639 Supporting information
- 640 S1 Checklist Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline
- 641 checklist
- 642 S1 Table Long COVID symptoms and temporal trends
- 643 S2 Table Exclusion of symptoms by comorbidities
- 644 S3 Table Patient characteristics in the 2018 and 2019 Flu seasons
- 645 S4 Table COVID-19 outpatient cases and controls
- 55 Table Detailed statistical data of the logistic and Poisson regression models for healthcare utilization
- 647
- 648



Figure